Eicosanoids are important mediators of both physiological and pathophysiological responses of the microcirculation. These biologically active lipid mediators can be produced locally by the cellular elements within the microvasculature (endothelium, pericytes, smooth muscle cells) as well as interstitial cells (e.g. fibroblasts, mast cells) and by various cells in the vascular compartment (e.g. leukocytes, platelets). Transcellular metabolism of intermediates produced by one cell type in close contact with another also has the potential to generate potent metabolites. This review integrates some of the older literature with recent developments in eicosanoid synthesis and release, the molecular advances in the enzymology and receptor specificity of the eicosanoids and the regulation by autocoids and inflammatory mediators. The potential roles of eicosanoids in regulation of local blood flow, vascular reactivity. angiogenesis and leukocyte adhesion and transmigration are discussed.
Introduction
Since the initial description in the 1930's of biologically active lipid factors derived from prostate gland and seminal fluid which contracted uterine smooth muscle, the eicosanoid field has undergone considerable maturation, with most of the progress occurring in the last 25 years. Much of the research in the 1970's focussed on the identification of products of the cyclooxygenase pathway, the characteristics of the different enzymes and their distribution, and the descriptions of the physiological and potential pathophysiological effects of these products on various cells, tissues and organ systems, in vitro and in vivo. The recognition that many of the anti-inflammatory effects of NSAIDS (non-steroidal anti-inflammatory drugs), such as aspirin and indomethacin, could be attributed to inhibition of cyclooxygenase, resulted in an intense period of development of new and more potent NSAIDS. In the late 1970's and early 1980's, the recognition that there were additional pathways for arachidonate metabolism spawned a new round of research investigating the lipoxygenase pathways and their pharmaceutical intervention. Interest in the eicosanoids waned somewhat in the later years of the 1980's with the discovery of new and more potent autocoids such as endothelial-derived relaxing factor (EDRF) and endothelins. However, progress in the field continued, ultimately resulting in the cloning and expression of most of the genes encoding enzymes involved in eicosanoid synthesis, various eicosanoid receptors, and even membrane transporters for the prostaglandins. The relatively recent demonstration that a novel isozyme of cyclooxygenase was selectively induced by mitogens and cytokines has resulted in renewed interest in the field. Pharmaceutical companies have rapidly responded to these new discoveries and now NSAIDS selective for the inducible isoform of cyclooxygenase are entering Phase I clinical trials.
The vascular endothelial cell has played a central role in much of this academic and industrial research activity. Strategically positioned to act as a biological response modifier between the blood and the tissue, the endothelium has a key role in monitoring blood-borne or local stimuli and responding with the appropriate, adaptive changes in function and mediator release. The endothelium is both a target and a source of autocoids, growth factors, cytokines, oxygen radicals, and hemostatic factors. However, although endothelial cells form a continuous lining, this lining is far from homogeneous. Important structural differences in endothelial junctions, interactions with basement membrane and other cells of the vascular wall, as well as great variation in the nature of receptors, and metabolic enzymes enable these cells to provide local, specialized functions selective for a given vascular bed.
Much of our initial understanding of the physiological roles of the vascular endothelium has been derived from a single cell source: human umbilical vein endothelial cells. These. and other large vessel endothelial cells derived from aorta and pulmonary artery of human, bovine and porcine sources, are relatively easy to grow. and thus data derived from these cells were often extrapolated to be characteristic of "all endothelium". This has certainly been the case for the arachidonic acid cascade; many reviews have patently stated that "Prostacyclin (PG12) is the major prostaglandin produced by all endothelial cells". Indeed, initial reports that endothelium derived from microvessels might synthesize major quantities of eicosanoids other than PGI, were met with considerable skepticism. However. recently. numerous reports from several different laboratories have verified these initial observations.
In the late 1970's and early 1980's, a number of methods were developed for the isolation of microvessels from brain [ 11, heart [3] and retina [3] . These methods enabled the study of biochemical properties of microvessela from these vascular beds and resulted in the novel observation that microvessels derived from bovine brain [4] , bovine heart [z], rabbit brain [5] and rabbit heart [6] demonstrated a glutathione-dependent prostaglandin E2 synthase and released substantial amounts of PGE,, often exceeding that of PGI,. The development of methods to isolate and culture endothelial cells from microvessels led to the observation that PGI, is not the major cicosanoid produced by microvessel endothelium. In 1983. our laboratory was the first to report that endothelial cells derived from rabbit heart synthesized PGE, as the major eicosanoid product [6] ; this report was supported shortly thereafter by similar observations with human dermal microvessel endothelial cells [7] , and rabbit renal microvessel cndothelial cells [8] . Later reports with human lung microvessel endotheliai cells [9] human synovial microvesset endothelial cells [ 101 and bovine glomerular endothelial cells [ 1 I ] have also described generation of PGE, in excess of PGI ,_ In addition to PGE, synthase, there are several reports-that indicate that PGD, synthase may also he expressed in select endothelial cells. In 1981 we reported that microves sels isolated from rat brain cxpresscd a unique. glutathione-dependent PGD synthase localized to the cytosol fraction of these preparations [ 1'21. At the time, the relative importance of this observation remained obscure since it appeared to he a rat specific phenomenon and potentially could have been due to mast cells or plial cells present in the preparations. However, a number of laboratories have recently reported that PGD, is the major eicosanoid generated by endothelial cells derived from the human cerebral microcirculation [ 13. lit] .
Much has been written about the proposed physiological and pathophysiological roles of PGI:. a potent vasodilator and inhibitor of platelet aggregation. H(owever. the focus of most reviews has been oh the role 01' eicosanoids in the vessel wall in the context of large vessels such as the aorta. Given the increasing body of evidence suggesting that PGE,. and posdhly PGD, are major eicosanoids produced in the micro~ircuiat.i~)~l. it is important to evaluate the available literature to elucidate what important, and possibly unique, roles these eicosanoids have at the level of the microva\;cutar cndothe- 
Pathways of arachidonate metabolism in microvessel endothelial cells
An interesting exercise is to gather reviews written about the pathways of arachidonic acid metabolism over the last two decades. The pathway has evolved from a single enzymatic pathway with a handful of identified products to an ever-increasingly complex web of pathways, some enzymatic and some non-enzymatic, with the potential to generate potent mediators affecting vascular tone, permeability, mediator release, platelet function, lymphocyte activation, leukocyte chemotaxis, cytoprotection, renal function, and ion transport. The major pathways for enzymatic arachidonic acid metabolism in endothelial cells are depicted in Fig. 1 .
The first step in the synthesis of eicosanoids is the release of arachidonic acid from membrane fatty acids, a step mediated by the cellular phospholipase A, family of enzymes, as well as possibly phospholipase C and D enzymes in concert with diglyceride lipases. With respect to the cyclooxygenase pathway, recent data now indicate the prostanoids (prostaglandins, prostacyclin and thromboxane) can be generated by two isozymes, known as cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). These two biochemically and pharmacologically distinct forms of cyclooxygenase (PGH synthase) catalyze the conversion of arachidonic acid to prostaglandin H2, the rate-limiting step in the prostanoid biosynthesis. The enzyme has two distinct activities, a cyclooxygenase activity which catalyzes the formation of PGG, from arachidonic acid and a peroxidase activity which reduces the hydroperoxide group of PGG, to form PGH *, the precursor for the prostanoids PGI,, PGD, , PGE,, PGF,, and TXA,. As the first catalytic step in the conversion of precursor arachidonic acid to prostaglandins, cyclooxygenase activity can play a crucial role in the generation of these lipid mediators of inflammation. Treatment of endothelial cells with agonists such as bradykinin, ATP, angiotensin II, endothelin, or thrombin results in an immediate release of prostaglandins; however, other stimuli such as cytokines and mitogens demonstrated a delayed, protein synthesisdependent effect on eicosanoid generation. The mechanism behind these divergent effects lay, at least in part, in the two cyclooxygenase isozymes.
Cyclooxygenase-1 was the enzyme originally isolated and cloned from murine, ovine and human sources [ I.5 171. Cyclooxygenase-2 was first identified as an early response gene, induced by phorbol esters in mouse fibroblasts [ 181. Later it was purified from human placenta and cDNAs were cloned from chicken [ 191 and human [20] sources. The two isozymes share about 60% amino acid identity and have similar molecular weights, approximately 70 kDa. However, COX-2 contains a unique sequence of 18 amino acid residues at the carboxyterminal [21] region and is more resistant to digestion by trypsin [22] . Both COX-1 and 2 are glycoproteins associated with membranes of the endoplasmic reticulum and nuclei [23, 24] , although recent data suggest that COX-2 may be selectively localized to the nuclear membrane [25] . The features essential for the enzyme activity are conserved in the two cyclooxygenases including the heme binding site, critical histidine residues in the active site, and glycosylation sites [26] . The transcripts of the two isozymes are also different in size; COX-1 is encoded by a 2.8 kb mRNA and the COX-2 transcript is about 4 kb. A substantial body of older literature indicated that endothelial cyclooxygenase activity was upregulated by a number of stimuli, including interleukin-1 CY and p (IL-l cr, IL-1 p>, tumor necrosis factor (Y (TNFcz), transforming growth factor p (TGFP), phorbol ester, lipopolysaccharide (LPS), and interferon y (IFNy). However, these earlier studies did not determine which cyclooxygenase was upregulated because the molecular tools for such analyses have only recently become available. If one extrapolates from observations with other cell types such as fibroblasts, it appears that COX-2 is selectively upregulated by cytokines and mitogens.
Regulation of COX-2 expression may result from both transcriptional and post-transcriptional activities; for example IL-l p has been reported to stabilize COX-2 mRNA in endothelial cells [27] . The effects of acidic fibroblast growth factor (aFGF) on endothelial COX activity were initially controversial. It appeared that aFGF downregulated large vessel endothelial 128,291 but upregulated microvessel-derived endothelial [28] eicosanoid synthesis. However, recent data using the molecular tools to distinguish the isozymes demonstrated that FGF downregulates COX-1 mRNA [30] , but elicits a transient upregulation of COX-2 mRNA [20] . Thus the apparent differences in responsiveness likely derive from differences in the net contributions of the two isozymes to total cellular prostanoid synthesis. Upregulation of COX-2 appears to play an important role in acute and chronic inflammation. Immunohistochemical studies of synovium from rheumatoid arthritis patients, and from animal models of rheumatoid arthritis demonstrated dramatic upregulation of COX-2 immunoreactivity [3 11, and anti-inflammatory steroids inhibit mitogen and cytokine induction of COX-2 [ IO,3 l-331. Our studies with endothelial cells derived from the synovial membrane of patients with human rheumatoid arthritis (HSE) indicated that IL-1 cr treatment of the cells at Pennsylvania State University on February 27, 2014 http://cardiovascres.oxfordjournals.org/ Downloaded from resulted in extraordinarily high levels of PGE, release. For example, a typical basal release of PGE, from unstimulated HSE ranged from 5 to 100 pg/2 X lo5 cells. Following 4-6 h of treatment with 10 U/ml IL-1 (Y it was not unusual to measure levels exceeding 50 ng/2 X lo5 cells! [341
Other enzymes in the eicosanoid pathway may also be regulated by cytokines and mitogens. For example, a recent report indicated that TGF/3 and IL-l p increase the expression of the cytoplasmic phospholipase A, gene in bovine pulmonary artery endothelial cells [35] . To date, studies of the molecular regulation of the PGH,-metabolizing enzymes (PGI, synthase, PGE, synthase, etc.> by mitogens and cytokines have been limited due to the lack of appropriate cDNAs, although a cDNA for the bovine PGI? synthase gene was recently described [36] . RNA blot studies indicated that the mRNA for PGI, synthase gene was increased about 3-fold by treatment with TNFcv [36] . PGD synthase cDNAs have recently been cloned [37] , but their expression in vascular endothelium has not been assessed. This may be important since the cDNA generated was for the brain-type PGD synthase, which was glutathione independent. A second type of PGD synthase, the so-called spleen-type, is glutathione dependent and appears to be a distinct gene product [38] .
There have been a number of reports suggesting that endothelial cells. at least from some sources, have the capacity to synthesize trace amounts of thromboxane A, (TXA?). However, the majority of these studies have used radioimmunoassay to quantitate TXA 2 release (measured as the stable metabolite, TXB,). Caution in interpretation of these results is advised, since cross-reactivity of the antisera could potentially account for these findings. With the recent cloning of the TXAz synthase gene [39] , and the availability of TXA, synthase cDNAs and antisera, it is now feasible to definitively demonstrate the presence of the mRNA and protein in vascular endothelial cells. A few reports have evaluated the distribution of TXA, synthase protein by immunohistochemistry; these studies have indicated little if any immunoreactivity in endothelial cells in the lung or umbilical cord; in contrast small vessels in the placenta appear to stain intensely for this enzyme 140,411
In mammalian tissues, three major forms of lipoxygenase, the 5, 12-and 15-lipoxygenases have been described, which catalyze the incorporation of dioxygen into positions 5. 12 and 15 of arachidonic acid respectively. The 5-lipoxygenase pathway gives rise to some of the most potent pro-inflammatory mediators, including the neutrophil chemoattractant, leukotriene B,. and the smooth muscle spasmolytic agents. leukotriene C,. D4 and E,. Residing in the cytosol of unstimulated cells, the 5-lipoxygenase enzyme translocates to a membrane fraction upon activation with appropriate stimuli. The activation is associated with a burst of leukotriene synthesis. Careful biochemical studies have clearly demonstrated that human umbilical vein endothelial cells do not ex.press 5-lipoxygenase activity and do not synthesize leukotrienes [42] . However. studies in vitro and in vivo have demonstrated that endothelial cells can generate leukotrienes C, and D., by a process termed " transcellular metabolism". Excess LTA,. generated by activated leukocytes such as neutrophils. can be converted by endothelial cells to leukotrienes C, and D, through the action of an endothelial-derived GSH-S-transferase activity [42] . Transcellular metabolism of leukotriene A, is augmented during the intimate and continuous interactions of cytokine-activated endothelial cells with neutrophils. and this metdbOkm can be substantially reduced by antibody blockade of cell adhesion molecules such as L-selectin and CD1 1 h/CD 18 (MAC-1) [43] (Fig. 2) .
Twelve-lipoxygenase, the first mammalian lipoxygenase described [44] , was initially found in platelets. It catalyzes the stereospecific incorporation of molecular oxygen into the C-12 of arachidonic acid to generate 12(S)-hydroperoxyeicosatetraenoic acid (12-HPETE), which is reduced by cellular GSH peroxidaset; to 12(S)-hydroxyeicosatetraenoic acid ( 12-HETE). This cytosolic enzyme also appears to undergo @an&cation to a membrane fraction when platelets are activated with thrombin [45] . Twelve-lipoxygenase cDNAs have been cloned. and I?- lipoxygenase mRNA in human umbilical vein endothelial cells has been described [46] . Immunohistochemical studies have also localized this enzyme to vascular endothelial cells [47, 48] .
Fifteen-HETE is also synthesized by vascular endothelial cells [49] ; however, it is now thought that in endotheha1 cells this arachidonic acid metabolite arises from cyclooxygenase activity rather than lipoxygenase activity; meclofenamate and indomethacin, potent inhibitors of cyclooxygenase but not lipoxygenase activity, inhibited 15-HETE production by human umbilical vein endothelial cells. Recent findings indicate that aspirin can acetylate COX-2, but in contrast to the complete inactivation seen with COX-1, aspirin-treated COX-2 retains the ability to enzymatically convert arachidonic acid to 1 SHETE; hence agents such as aspirin have the potential to switch the enzyme activity from prostaglandin to 15-R-HETE formation [50] .
During the last decade, various investigators have recognized the role of the cytochrome P450 monoxygenase pathway in the generation of a novel group of biologically active metabolites. Cytochrome P450 represents a unique family of hemoproteins that serve as terminal acceptors in the NADPH-dependent mixed function oxidase system, a system which catalyzes the oxidative transformation of endogenous (e.g. fatty acids, steroids, prostaglandins, leukotrienes) and exogenous (e.g. polycyclic aromatic hydrocarbons) substrates [51] . This enzyme system, in the presence of NADPH and molecular oxygen, is capable of metabolizing arachidonic acid to a number of oxygenated metabolites, including (1) four regioisomeric epoxides (5,6; 8,9; 11 ,I 2; 14,15 EETs) which are subsequently hydrolyzed to the corresponding diol derivatives (DHTs), (2) six regioisomeric cis-trans conjugated mono-hydroxyeicosatetraenoic acids (HETEs), and (3) o and w-l alcohols [52, 53] . Several reports have described the production of the epoxides (EETs) by vascular endothelial cells; 14,15-EET appears to be the major EET produced by these preparations [54, 55] .
A recent study suggested a role for a cytochrome P450-derived arachidonic acid metabolite as the mediator of endothelium-dependent hyperpolarizing activity in the coronary microcirculation [56] . This endothelium-derived hyperpolarizing factor (EDHF) hyperpolarizes vascular smooth muscle cells via activation of K+ channels, and contributes to the dilator effect of bradykinin in a number of vascular beds. Evidence suggesting that the EDHF, at least in the rat coronary microcirculation, was a cytochrome P450 metabolite included inhibition of the EDHF-type dilation with inhibitors of phospholipase A, (quinacrine) and by the cytochrome P450 inhibitor, SKF525a. However, the nature of the proposed cytochrome P450 metabolite has not been resolved at this time. Cytochrome P450 metabolites of arachidonic acid have a number of biological activities which could potentially impact on microcirculatory function including stimu- lation of peptide hormone release, inhibition of Na'K+ ATPase, vasodilation, Ca*+ mobilization, inhibition of platelet aggregation and stimulation of endothelial proliferation and angiogenesis in vivo.
Lipoxins, a group of structures generated by mammalian as well as more primitive species [57] , are potent modulators of vascular and inflammatory cell activity. With respect to endothelial cells, lipoxin generation is yet another example of transcellular metabolism. Bidirectional interactions between endothelial cells and neutrophils, or endothelial cells and platelets demonstrated the potential to generate unique arachidonic acid metabolites (Fig. 2) . Lipoxins are lipoxygenase-derived, biologically active eicosanoids, generated predominantly as a consequence of transcellular metabolism amongst neutrophils, platelets, eosinophils, macrophages, and possibly, to a lesser extent endothelial cells [58, 59] . The formation of lipoxins in human cell types can be generated by either initial oxygenation of arachidonic acid by 5-lipoxygenase followed by interactions with 12-lipoxygenase; or alternatively bygeneration in vivo. 8-epi-prostaglandin F,, is one of the most abundant of the F, isoprostanes formed under physiological conditions in humans. However, very recent data indicate that 8-epi-F, ci may be formed as a cyclooxygenase-l-dependent product, at least in platelets [61] . Enzymatic epiprostane formation by endothelial cells has not been described to date.
Physiological and pathophysiological roles of eicosanoids in the microcirculation
Eicosanoids impact a number of critical functions of the microcirculation in which the endothelial cell plays a pivotal role, including coagulation/fibrinolysis, vascular reactivity and control of blood flow, permeability, leukocyte adhesion and transmigration and local control of immune cell function. The diverse and often confusing array of biologic activities of the eicosanoids is gradually being clarified with the identification and molecular cloning of various receptors for eicosanoids.
One of the most perplexing attributes of eicosanoids was the divergent actions of a given metabolite on different cells, different blood vessels, different vascular beds and different species. In the last few years, a reasonable explanation for at least some of these apparent discrepancies has been resolved with the identification, purification and cloning of selective eicosanoid receptors. For a more detailed review of this area. the reader is referred to two excellent recent publications [62, 63] . These studies have indicated that each prostanoid has a specific receptor, and further, that there are several receptor subtypes for prostaglandins of the E series. In general, eicosanoid receptors are coupled to intracellular effector pathways by G-proteins. Table I summarizes the current data on prostanoid receptors with respect to those identified or potentially identified in vascular cells.
Subtypes of eicosanoid receptors: lipand affinity and distribution

Coagulation / fibrinolysis
The principal role of eicosanoids in the control of coagulation/fibrinolysis has been the control of platelet function. Endothelial-derived eicosanoids, i.e. PGIZ. and to a lesser extent PGE,, inhibit platelet aggregation (but not the initial platelet adhesion to exposed smooth muscle cells or matrix), primarily through a mechanism that results in the elevation of CAMP [64, 65] . Endothelial-derived eicosanoids (PGI,, PGE,) play an important role in limiting the size of platelet thrombus by allowing the adhesion of a single layer of platelets, yet inhibiting the multicellular aggregation of platelets or platelet-leukocyte aggregates. Thus these eicosanoids allow the sealing of an initial wound but do not promote occlusion of the vessel leading to the wound site. Another endothelial-derived mediator, nitric oxide (NO), also potently inhibits the aggregation and adhesion of platelets by raising levels of platelet cGMP. In addition, the antiaggregatory effects of PGIz and NO are synergistic at subthreshold concentrations [66] . The release of PGI?/PGE, and of NO are coupled in cultured endothelial cells and in the blood-perfused microcirculation [67, 68] . A greater synergistic dis-aggregatory effect on platelet clots is obtained when a third important endothelial cell product, tissue-type plasminogen activator (tPA). is present together with PGI, and NO [63] . Fibrin elicits the release of both PGI, and tPA from endothelial cells, resulting in locally released PGI? and tPA [70] , which in turn can feedback and stimulate fibrinolysis and platelet disaggregation.
Eicosanoid effects on local blood flow. permeability, leukocyte adhesion and diapedesis
Eicosanoids exert a variety of activities that impact on local blood flow. vascular reactivity and \,ascular perme- The early inflammatory response is characterized by an overlapping sequence of events: (1) changes in arteriolar diameter characteristically followed by (2) vasodilation and increase in venular permeability with pronounced macromolecular leakage, and increased formation of tissue edema and (3) diapedesis and migration of leukocytes into the area of injury. In this sequelae of inflammatory responses, eicosanoids play a variety of roles. As discussed above, prostaglandins E, and I? contribute to the vasodilation and exacerbate permeability elicited by primary stimuli such as histamine, bradykinin, sensory neuropeptides and leukotrienes. However, prostaglandins can also reduce mediator release; PGE,, for example, can reduce the in vivo release of histamine evoked by antigens, and indomethacin, a cyclooxygenase inhibitor, can substantially increase antigen-provoked release of histamine, as well as enhancing the antigen-provoked release of histamine [78] . Initial vasoconstrictor responses may be mediated, at least in part, by the leukotrienes LTC, and LTD,. Lipoxygenase inhibitors offer some protection, reducing plasma leakage and decreasing the number of migrating leukocytes, as well as inhibiting the initial vasoconstriction. Leukotrienes, released from both blood-borne and tissue-resident cells, as well as potentially generated via transcellular metabolism, probably play important roles in the acute inflammatory response. Local administration of LTB, to the hamster cheek pouch or rabbit teniussimus muscle causes leukocyte adhesion to vessels of all sizes and results in subsequent leukocyte emigration to the perivascular interstitium. This process is accompanied by plasma leakage, a process entirely dependent on local blood flow and intact, adhesive leukocytes [79-821. Electron microscopy, using markers for plasma proteins, suggests that leukotrienes promote leakage of plasma between gaps of apparently contracted endothelial cells [83, 84] .
Lipoxins may also play an important counter-regulatory role in inflammation. Application of lipoxin A, to the hamster cheek pouch elicits vasodilation and an increase in blood flow, in the absence of concomitant changes in permeability or leukocyte interactions [85] . Lipoxins inhibit adhesion of neutrophils to endothelial cells and inhibit neutrophil and eosinophil chemotaxis . At present, most of the available data indicate that lipoxins serve as natural or endogenous downregulators (so-called chalones) of the inflammatory response.
Study of the mechanism of the action of aspirin has resulted in a number of seminal contributions to our understanding of the role of eicosanoids. The observations of Vane and colleagues were the first to demonstrate that this salicylic acid derivative potently inhibited prostaglandin generation; more recent work demonstrated that this was a consequence of acetylation of key amino acids in the active site of cyclooxygenase (reviewed in [91] >. Interestingly, aspirin-acetylated COX-2 enzymatically generates 15HETE, which carries its Cl 5 alcohol predominantly in the R configuration (ISR-HETE); 15R-HETE is also a product of arachidonate metabolism by cytochrome P450 in cells [20, 50, 53, 92] . Thus aspirin treatment of cells under the influence of inflammatory or mitogenic stimuli could preferentially divert arachidonic acid metabolism to 15-HETE products such as lipoxins.
The process of leukocyte diapedesis is also modulated by products of arachidonate metabolism. Several arachidonic acid metabolites are neutrophil chemoattractants. including LTB,, and 12(R)-hydroxyeicosatrienoic acid (12(R)-HETrE) [93] . PGE, and LTB, can stimulate T-cell migration across a Matrigel basement membrane in vitro [94] . The effect of PGE, on T-cell migration was chemokinetic in nature whereas the LTB, response was a true chemotactic response. Interestingly, the same concentrations of PGE, and LTB, that stimulated T-cell migration also enhanced T-cell surface expression and secretion of matrix metalloproteinases (MMP), specifically MMP-2 (gelatinase A), and MMP-9 (gelatinase B) [94] . PGE, has also been shown to inhibit the transendothelial migration of T-cells in vitro [95] , although PGE, had no effect on T-cell-endothelial cell binding. In vitro studies have demonstrated that LXA, can inhibit neutrophil chemotaxis stimulated by LTB, or fmet-leu-phe [88] .
Eicosanoids and flow-dependent responses
If an arteriole is temporarily occluded, the red blood cell velocity in proximal, parallel arteriolar branches is increased, and this increase in flow velocity is followed by a delayed increase in arteriolar diameter; this response has been termed jlow-dependent dilation. At the onset of the occlusion, when the blood flow velocity starts to increase, careful observations noted that the arteriolar diameter was initially slightly decreased. These two phenomena result in an increase in wail shear stress which is directly proportional to velocity and inversely proportional to diameter. After a delay ranging from 6 to 15 s the diameter of the arteriole increases. restoring red blood cell velocity to a steady state.
The flow-mediated vasodilation has been shown to be endothelium-dependent in a number of arteriolar preparations [96, 97] . Recent studies by Koller and colleagues have strongly suggested that an arachidonic acid metabolite is the primary mediator of this response [98] . Application of inhibitors of nitric oxide (NO) synthesis do not significantly affect the dilation whereas inhibitors of cyclooxygenase, such as indomethacin or meclofenamate, completely inhibited the arteriolar dilation in response to the increased red blood cell velocity. Thus locally generated endothelial-derived prostaglandins (probably PGE, and, to a lesser extent, PGI?) play an important role in this novel regulatory mechanism which can provide substantial increases in blood flow.
Another important local mechanism regulating arteriolar resistance is the myogenic response. This response is due to the ability of vascular smooth muscle to constrict in response to increased transmural pressure, and conversely to dilate when transmural pressure is reduced. In isolated coronary arterioles, under conditions which permit control of intraluminal pressure and flow, it was shown that myogenic tone attenuates flow-induced dilation [99] . In contrast to the flow response, however, the myogenic response of arterioles may or may not be endothelial dependent, varying somewhat from one vascular bed to another, and also perhaps, with the size of vessel. In larger vessels, such as the canine basilar artery, the myogenic response was reported to be dependent on an intact endothelium [ 1001. In contrast, Falcone and co-workers found that the myogenic response of isolated skeletal muscle first-order arterioles was endothelium independent [loll. Hwa and Bevan also concluded that the myogenic response of isolated 75-150 pm rabbit ear arterioles was endothelium independent [102] , and similar results were reported by Kuo et al. in isolated coronary arterioles [96] . These results suggest that the mechanisms which contribute to the myogenic response may exhibit considerable heterogeneity. The contribution of locally produced humoral mediators to the myogenic response is also variable. The endothelium could potentially mediate pressure-or stretch-induced vasoconstriction either by the release of an endothelial-derived constriction factor, or by decreasing the production of endothelial-derived relaxation factors. Katusic et al. reported that stretch-induced vasoconstriction of isolated canine basilar arteries was mediated by release of a cyclooxygenase-dependent constricting factor from the endothelium [ 1011; however. in another study stretchinduced contraction of feline pulmonary arteries was only partially mediated by cyclooxygenase products [ 1031. Hill and coworkers [ 1041 found that the myogenic response of skeletal muscle arterioles was potentiated by inhibitors of cyclooxygenase, indicating that endogenuus vasodilator prostaglandins attenuated myogenic activity. These authors also observed that inhibitors of NO (EDRF), while reducing basal vascular tone, did not augment myogenic vasoconstriction.
Endothelial prostaglandin synthesis is altered in certain disease states (e.g. atherosclerosis, diabetes, hypertension); dysfunctional production of endotheiial eicosanoids (as well as other endothelial-derived mediators such as NO and endothelin) in response to either flow or pressure could impair important, local regulatory mechanisms which control microvascular flow and capillary pressure and contribute further to the pathogenesis of these disorders. Huang et al. [ 1051 investigated the myogenic response of isolated cannulated arterioles derived from the rat cmmaster muscle of Wistar-Kyoto (WKY), spontaneously hypertensive (SHR) and normal Wistar (NW) rats. These authors found that in early hypertension, the pressure-induced arteriolar constriction was increased, an effect which appeared to he the result of enhanced production of endothelium-derived constrictor factors, primarily prostaglandin H?. The same group also found that shear-stress-induced dilation was attenuated in skeletal muscle arterioles of hypertensive rats, a response that appeared to be due FO a loss of NO synthesis and release in response to shear stress since prostaglandin-mediated dilation appeared to be normal [ 1061.
Angiogenesis
Angiogenesis, the process of formation of new blood vessels from the established microcirculation. contributes to a number of normal responses, i.e. embryonic development, menses and wound healing, and to a large variety of pathological conditions, such as solid tumor growth, collateral growth, diabetic retinopathy, rheumatoid arthritis, hemangiomas, psoriasis, scleroderma, and neovascular glaucoma. The process of angiogenesis can be subdivided into four endothelial-dependent, sequential, and mechanistic steps: (1) proteolytic degradation of the vascular basement membrane and interstitial matrix, (2) endothelial migration, (3) proliferation of endothelial cells, and (4) capillary loop formation.
Eicosanoids participate in, although arc nut essential for, a number of the phenomena associated with angiogenesis. For example, an inflammatory response characterized by vasodilation, increased permeability and leukocyte extravasation often precedes and accompanies angiogenesis. Although growth factors (basic fibroblast growth factor. acidic fibroblast growth factor, vascular endothelial growth factor, platelet-derived growth factor) are thought to be the major direct angiogenic factors (i.e. they can induce en-dothelial proliferation or migration in vivo and in vitro), recent studies by Stolz et al. [107] suggest that 12(R)-HETrE, a cytochrome P450-derived eicosanoid, is capable of directly stimulating microvessel endothelial cell proliferation and capillary formation in vitro. E series prostaglandins are potent angiogenic stimuli in the rabbit cornea and chick embryo angiogenesis models, although these eicosanoids do not support endothelial migration or proliferation in vitro [ 108-1111. Since prostaglandin levels are elevated in wounds, inflammatory exudates, and tumors, it is likely that PGs modulate the initiation or progression of angiogenesis. Fibroblast growth factor is also a potent inducer of cyclooxygenase-2 in microvascular endothelial cells [28,1 121.
Nitric oxide and prostaglandin synthesis
Since the initial description of NO as "EDRF" by Furchgott in 1980 [ 1131 it has been recognized that NO and PGI, (and, to a lesser extent, PGE,) share a number of important properties. Both are vasodilators. Many, although not all, stimuli for NO release are also potent stimuli for PG release. Bradykinin, and acetylcholine, for example, induce vasodilation that is dependent on both NO and PG production [ 1141. Cyclooxygenation of arachidonic acid or conversion of L-arginine to NO may occur by either constitutive or inducible isoforms of the respective enzymes (COX or nitric oxide synthase (NOS)). In large vessel and microvessel endothelial cells, cytokines upregulate NO and PG production [28,112,1 15-l 171, and the induction of the inducible form of both enzymes is blocked by glucocorticoids [ 10, 32, 33, 118] . Administration of LPS to rats increased plasma PGEz and nitrite/nitrate production, and both responses were suppressed by glucocorticoids [ 1191. Thus it is not surprising that an emerging area of investigation is the possible interactions of these two important pathways.
Several recent studies suggest that the PG and NO biosynthetic pathways may modulate each other. For example, LPS induction of PGE, in rats was inhibited by NOS inhibitors, and further, sodium nitroprusside mimicked the effects of LPS [120] . In a rabbit model of renal inflammation (uretal obstruction), the increase in cyclooxygenase activity was enhanced by NO [121] . In vitro evidence for direct NO promotion of eicosanoid synthesis in endothelial cells has been equivocal [ 122, 123] , although NO synthesis was required for LPS induction of PGE, production by macrophages [124] . A recent study by Dawidge and coworkers suggested that stimulating the synthesis of NO production by endothelial cells increases eicosanoid production, apparently by activating cyclooxygenase [125] . There are also data to indicate that eicosanoids can modulate NO release and NOS expression. Arachidonic acid and LTB, stimulate NO generation in platelets and neutrophils [ 1261. PGE, reduces IL-l-induced iNOS induction in mesangial cells [ 1271. and eicosanoids may also modulate expression of iNOS induced by TNFcr and TGF/3 [ 1281.
The molecular mechanism for the interaction of these two pathways is presently unclear. However, many of the effects mediated by NO are due to its interaction with iron or iron-containing enzymes. For example, NO binds to the heme-Fe" prosthetic group of soluble guanylate cyclase; the subsequent increase in levels of cyclic GMP mediates the anti-platelet and vasodilator effects of NO [I 291. The cytotoxicity of NO is thought to derive from an interaction with iron-sulfur centers of certain enzymes key to the respiratory cycle and DNA synthesis [ 1281. Cyclooxygenase, with its iron-heme center that confers the hydroperoxidase function, is an opportune target for NO [130] . Alternatively nitrosation of other targets on cyclooxygenase (tyrosine, free cysteines) could potentially alter activity of this key prostanoid-synthesizing enzyme. NO may also regulate cyclooxygenase transcription through actions on one or more transcription factors.
Future perspectives
Nearly 70 years have passed since the seminal observations of von Euler and colleagues first focussed the attention of the scientific community on the eicosanoids. The future of this field holds incredible opportunities -with further applications of molecular biology we stand to gain new information concerning the molecular mechanisms involved in the regulation of eicosanoid biosynthesis, the "cross-talk" between the NOS and COX pathways, and most importantly in the pathogenesis of various diseases which leads to dysfunctional endothelial synthesis and metabolism of eicosanoids. The elucidation of the transcription factors involved in the regulation of eicosanoid and NO synthesis in response to shear, pressure, injury and inflammatory cytokines offers a wide spectrum of new opportunities for investigation. The development of genetically modified mouse models over-expressing, mutant-expressing or null for various enzymes or receptors in the eicosanoid pathway holds promise for exciting new in vivo studies. For example, a recent report by Chen and coworkers [I3 11 indicated that targeted disruption of the 5-lipoxygenase gene had no major effects on the phenotype, producing an apparently normal healthy mouse. However, the 5-lipoxygenase null mouse did demonstrate selective alterations in certain inflammatory responses -for example, although these animals were similarly sensitive to endotoxin-induced shock as the wild-type mouse, the 5-lipoxygenase null mouse was resistant to the lethal effects of platelet activating factor-induced shock. The 5-lipoxygenase null mouse also demonstrated a reduced inflammatory response to arachidonic acid.
Initial characterizations of the phenotypes of COX-1 and COX-2 deficient mice were also recently reported [ 132, 133] . The COX-1 null mouse had few phenotypic abnormalities. Homozygotes were unable to cross-breed although viable offspring were produced when homozygotes were mated with heterozygotes of either sex. This observation is not surprising in view of the well-described roles for prostaglandins in ovulation, spermatogenesis and parturition. Other defects of the COX-1 null mouse included the inability of arachidonic acid to elicit platelet aggregation, a reduced response to arachidonic acid in a standard ear edema model, and a lack of stomach ulceration in untreated animals and a reduced ulcerative response in NSAID-treated animals [ 1321. This model offers considerable potential for those interested in the role(s) of endothelial-derived eicosanoids in normal physiological responses, the role(s) of leukocyte adhesion and degranulation in the ulcerative response to NSAIDS and numerous other interesting questions.
In contrast to the COX-1 null mouse, the COX-2 null mouse was not healthy; progressive nephropathy was observed as early as 6 weeks and led to death 8-16 weeks after birth. The primary defect appeared to be due to a premature halt in the differentiation and maturation of the kidney resulting in only a small percentage of intact nephrons. COX-2 deficient mice did not demonstrate a reduced response in the arachidonic acid ear edema test, although this may have been due to the short time point (2 h) used [ 1331.
The availability of these and other genetic models now in development heralds a new era for eicosanoid biology, in which molecular biology and physiology will synergize to test the molecular insights and hypothesis in integrated in vivo systems.
